Morgan Stanley Maintains GW Pharmaceuticals PLC- ADR to Overweight with Price Target $160.00

Brokerage firm Morgan Stanley Maintains its rating on GW Pharmaceuticals PLC- ADR(NASDAQ:GWPH). In a research note issued to the investors, the brokerage major Raises the price-target to $160.00 per share. The shares have been rated Overweight. The rating by Morgan Stanley was issued on Sep 27, 2016.

In a different note, On Sep 26, 2016, Cantor Fitzgerald said it Maintains its rating on GW Pharmaceuticals PLC- ADR. In the research note, the firm Raises the price-target to $165.00 per share. The shares have been rated ‘Buy’ by the firm.

GW Pharmaceuticals PLC- ADR (GWPH) made into the market gainers list on Fridays trading session with the shares advancing 2.12% or 2.76 points. Due to strong positive momentum, the stock ended at $132.73, which is also near the day’s high of $135.16. The stock began the session at $131.54 and the volume stood at 8,45,719 shares. The 52-week high of the shares is $135.16 and the 52 week low is $35.83. The company has a current market capitalization of $2,889 M and it has 2,17,65,014 shares in outstanding.

GW Pharmaceuticals PLC- ADR(GWPH) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q3.Company reported revenue of $3.10M. Analysts had an estimated revenue of $3.66M. Earnings per share were $-0.06. Analysts had estimated an EPS of $-1.21.

GW Pharmaceuticals plc is a United Kingdom-based biopharmaceutical company. The Company is engaged developing a portfolio of cannabinoid medicines including Sativex for the treatment of multiple sclerosis spasticity and cancer pain and Epidiolex for the treatment of childhood epilepsy. The Company also engaged in developing cannabinoids medicines containing controlled substances as well as plant-based prescription pharmaceutical products. The Company’s product Sativex is approved in 27 countries and is used as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). The Sativex is also in Phase III clinical development for the treatment of cancer pain the indication for the United States market.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *